Innovita Biological Technology Co. Ltd. A (688253) - Net Assets
Based on the latest financial reports, Innovita Biological Technology Co. Ltd. A (688253) has net assets worth CN¥2.10 Billion CNY (≈ $306.70 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.23 Billion ≈ $326.60 Million USD) and total liabilities (CN¥136.00 Million ≈ $19.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Innovita Biological Technology Co. Ltd. (688253) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.10 Billion |
| % of Total Assets | 93.91% |
| Annual Growth Rate | 25.17% |
| 5-Year Change | 177.99% |
| 10-Year Change | N/A |
| Growth Volatility | 48.54 |
Innovita Biological Technology Co. Ltd. A - Net Assets Trend (2020–2025)
This chart illustrates how Innovita Biological Technology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See 688253 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Innovita Biological Technology Co. Ltd. A (2020–2025)
The table below shows the annual net assets of Innovita Biological Technology Co. Ltd. A from 2020 to 2025. For live valuation and market cap data, see 688253 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.05 Billion ≈ $300.28 Million |
+2.94% |
| 2024-12-31 | CN¥1.99 Billion ≈ $291.70 Million |
+8.22% |
| 2023-12-31 | CN¥1.84 Billion ≈ $269.54 Million |
+9.04% |
| 2022-12-31 | CN¥1.69 Billion ≈ $247.20 Million |
+128.85% |
| 2021-12-31 | CN¥738.17 Million ≈ $108.02 Million |
+10.50% |
| 2020-12-31 | CN¥668.01 Million ≈ $97.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Innovita Biological Technology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 181.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥872.16 Million | 42.50% |
| Other Components | CN¥1.18 Billion | 57.50% |
| Total Equity | CN¥2.05 Billion | 100.00% |
Innovita Biological Technology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Innovita Biological Technology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United States Steel Corp
BA:X
|
$1.18 Billion |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd A
SHG:600639
|
$1.18 Billion |
|
CVR Partners LP
NYSE:UAN
|
$1.18 Billion |
|
Zee Entertainment Enterprises Limited
NSE:ZEEL
|
$1.18 Billion |
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
$1.18 Billion |
|
Beijing Sanju Environmental
SHE:300072
|
$1.18 Billion |
|
Genting Plantations Bhd
KLSE:2291
|
$1.18 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
$1.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovita Biological Technology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,993,388,465 to 2,052,069,396, a change of 58,680,931 (2.9%).
- Net income of 144,473,257 contributed positively to equity growth.
- Dividend payments of 75,233,455 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥144.47 Million | +7.04% |
| Dividends Paid | CN¥75.23 Million | -3.67% |
| Other Changes | CN¥-10.56 Million | -0.51% |
| Total Change | CN¥- | 2.94% |
Book Value vs Market Value Analysis
This analysis compares Innovita Biological Technology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.97x to 3.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥6.54 | CN¥58.70 | x |
| 2021-12-31 | CN¥7.23 | CN¥58.70 | x |
| 2022-12-31 | CN¥12.42 | CN¥58.70 | x |
| 2023-12-31 | CN¥13.54 | CN¥58.70 | x |
| 2024-12-31 | CN¥14.61 | CN¥58.70 | x |
| 2025-12-31 | CN¥14.98 | CN¥58.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovita Biological Technology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.04%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.23%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.11x
- Recent ROE (7.04%) is below the historical average (23.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 85.59% | 55.10% | 1.33x | 1.17x | CN¥504.69 Million |
| 2021 | 16.29% | 36.78% | 0.41x | 1.08x | CN¥46.44 Million |
| 2022 | 8.92% | 33.74% | 0.23x | 1.15x | CN¥-18.25 Million |
| 2023 | 9.44% | 36.39% | 0.23x | 1.12x | CN¥-10.25 Million |
| 2024 | 12.38% | 39.73% | 0.28x | 1.11x | CN¥47.52 Million |
| 2025 | 7.04% | 34.23% | 0.19x | 1.11x | CN¥-60.73 Million |
Industry Comparison
This section compares Innovita Biological Technology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovita Biological Technology Co. Ltd. A (688253) | CN¥2.10 Billion | 85.59% | 0.06x | $1.18 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.